Last edited by Digore
Wednesday, July 22, 2020 | History

2 edition of Pharmacokinetics of cefoperazone in healthy controls and patients with cystic fibrosis found in the catalog.

Pharmacokinetics of cefoperazone in healthy controls and patients with cystic fibrosis

Steven-Harold.* Schachter

Pharmacokinetics of cefoperazone in healthy controls and patients with cystic fibrosis

by Steven-Harold.* Schachter

  • 49 Want to read
  • 5 Currently reading

Published .
Written in English


The Physical Object
Pagination115 leaves
Number of Pages115
ID Numbers
Open LibraryOL16360010M

Pharmacokinetics of a drug depends on patient-related factors as well as on the drug’s chemical properties. Some patient-related factors (eg, renal function, genetic makeup, sex, age) can be used to predict the pharmacokinetic parameters in populations. Pharmacokinetics is the aspect of pharmacology dealing with how drugs reach their site of action and are removed from the body. The following processes govern the rate of accumulation and removal of drug from an organism– absorption, distribution, metabolism, and excretion. Details of pharmacokinetics are provided in the following sites in.

Pharmacokinetics is a fundamental scientific discipline that underpins applied therapeutics. Patients need to be prescribed appropriate medicines for a clinical condition. The medicine is chosen on the basis of an evidence-based approach to clinical practice and assured to be compatible with. The extent of bioavailability is the chief criterion in the selection of an oral cephalosporin. For most of the pro-drugs (which may have varying susceptibility to human nonspecific esterases), bioavailability often does not exceed 50%, while the unmodified compounds (e.g. cefaclor and ceftibuten) are usually better absorbed, with the exception of cefixime.

  Summary. Cefoperazone is a new piperazine cephalosporin derivative which has a broad antibacterial activity against aerobic and anaerobic gram-positive and gram-negative cocci and bacilli, including Pseudomonas aeruginosa. In studies of the intramuscular (i.m.) administration of cefoperazone at doses of , , and 1 g, mean peak serum concentrations w 33, and 67 μg/ml at 1 hr. Pharmacokinetics can be simply described as the study of 'what the body does to the drug' and includes: • the rate and extent to which drugs are absorbed into the body and distributed to the body tissues • the rate and pathways by which drugs are eliminated from the body by metabolism and excretion.


Share this book
You might also like
International Corporate Finance

International Corporate Finance

Philadelphia music engraving and publishing, 1800-1820

Philadelphia music engraving and publishing, 1800-1820

good steward

good steward

KUMAMOTO FAMILY BANK, LTD. (THE)

KUMAMOTO FAMILY BANK, LTD. (THE)

spelling experimenter and phonetic investigator

spelling experimenter and phonetic investigator

Catalogue of fine Chinese export porcelain... which will be sold by auction by Sotheby, Parke Bernet & Co... at their large galleries... New Bond Street, Londn... [on] Tuesday, 26th June, 1979....

Catalogue of fine Chinese export porcelain... which will be sold by auction by Sotheby, Parke Bernet & Co... at their large galleries... New Bond Street, Londn... [on] Tuesday, 26th June, 1979....

Niagara student conference

Niagara student conference

The message of a strenuous life

The message of a strenuous life

Scenes from the life of Nickleby married

Scenes from the life of Nickleby married

US interests and the global environment

US interests and the global environment

Muted horizon

Muted horizon

God and evil

God and evil

Signing Smart workshop-in-a-box

Signing Smart workshop-in-a-box

Pharmacokinetics of cefoperazone in healthy controls and patients with cystic fibrosis by Steven-Harold.* Schachter Download PDF EPUB FB2

Pharmacokinetics of ceftazidime during continuous and intermittent infusion in adult cystic fibrosis patients, p. In J. Mouton (ed.), Pharmacokinetic and pharmacodynamic studies of betalactam antibiotics in volunteers and patients with cystic fibrosis.

University of Rotterdam, Rotterdam, the Cited by: To evaluate the pharmacokinetics and pharmacodynamics of ceftaroline in adults with cystic fibrosis (CF). Design. Open‐label, single‐center, prospective study.

Setting. University‐affiliated teaching institution. PatientsCited by: Methicillin-resistant Staphylococcus aureus (MRSA) is a prevalent pathogen in patients with cystic fibrosis (CF) associated with increased morbidity. Ceftaroline fosamil is an intravenous (IV) cephalosporin with activity against MRSA.

There are minimal data regarding dosing in the CF population. The objective of this study was to determine the pharmacokinetic and pharmacodynamic profile of IV Cited by: 2. The authors evaluated the pharmacokinetics of cefoperazone and sulbactam in 9 liver transplant patients.

Cefoperazone and sulbactam were administered as an intravenous infusion over 30 minutes every 12 hours for six doses, and multiple blood samples were collected immediately after the first dose (administered during the surgery) and after the last by: 9.

Pharmacokinetics and pharmacodynamics of continuous infusion of cefepime in cystic fibrosis patients, and stability of cefepime during simulated continuous infusion administration By Pål Falck Sprauten Laboratory for Clinical Pharmacy Research University of Southern California USA And Department of Pharmacology School of Pharmacy.

The pharmacokinetics of cefoperazone were studied and compared in four normal subjects and six patients with hepatosplenic schistosomiasis (HSS) with mild liver disease but marked portal hypertension.

All subjects received a 2 g intravenous infusion of cefoperazone over 15 min. The pharmacokinetics (PK) of patients with cystic fibrosis (CF) has been reported to considerably differ from that in healthy volunteers since the s [1,2,3,4].This was especially true for early studies in patients with CF for β-lactams with high protein binding (such as dicloxacillin and cloxacillin) [5,6].These early studies compared mostly adolescent and presumably rather morbid.

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

Antimicrob Agents Chemother. Oct 21;60(11) doi: /AAC However, in more severely ill patients who do not have cystic fibrosis renal blood flow, as a fraction of cardiac index, is not increased.

Previous studies of ceftazidime pharmacokinetics in severely ill patients show a wide variation in estimated clearance and volume of distribution [ 31 – 33 ] although in every study, including the present. Six noninfected CAPD patients were given a fixed dose of cefoperazone (2 g) and sulbactam (1 g) either intravenously or intraperitoneally over 10 min in a randomized, two-way crossover fashion.

study of healthy volunteers, hospitalized general ward patients, and critically ill patients, atorvastatin maximal con-centration (C max) and AUC 0 to 24 hours after administration were about and fold higher, respectively, in critically ill patients with sepsis (phealthy volunteers.

Several groups have investigated the pharmacokinetics of cefoperazone in healthy volunteers and have compared them with those of both first and second generation cephalosporins as well as with cefotaxime, the new third generation cephalosporin.

Intramuscular administration resulted in high serum concentrations, i. for to 1 g doses, Introduction to Pharmacokinetics and Pharmacodynamics Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabo-lism, and excretion.

Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. The pharmacokinetics of cefoperazone after i.p. and/or i.v. administration were studied in 12 CAPD patients. After i.v. injection, the plasma half-life was ± h, the total clearance amounting to ± ml/min.

Peritoneal clearance was calculated to be ±1 ml/min. After peritoneal instillation, the bioavailability was ±5%. Cefoperazone exhibits a longer half-life of elimination than older members of the group and good penetration into organic bone.

The pharmacokinetics of cefoperazone had been investigated in a number of animal species including unweaned calves, horse, dog, buffalo calves, cross bred calves, and sheep.

The aim of the study was to. The pharmacokinetic and microbiological properties of a new third generation cephalosporin, cefoperazone, when given by the intramammary route to the cow are described. Cefoperazone is excreted from the udder over a three- to five-day period following a single infusion of mg in an oil base into each of all four quarters.

By the fifth milking after treatment the mean bucket (composite. Shyu WC, Pittman KA, Wilber RB, et al "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (): Spyker DA, Richmond JD, Scheld WM, Bolton WK "Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients." Am J Nephrol 5 ():   This is an open-label, single center, prospective study of patients with a diagnosis of cystic fibrosis (CF) and a history of methicillin-resistant Staphylococcus aureus (MRSA), also known as oxacillin-resistant Staphylococcus aureus (ORSA), being treated with intravenous ceftaroline.

RESULTS: Total fourteen patients were enrolled. Volume of distribution at steady state (V ss) of cefoperazone and sulbactam for initial doses ( ± and L, respectively) increased significantly compared with those in healthy volunteers (P = for CFP, P = for SUL).

J Cyst Fibros. Nov 2. pii: S(17) doi: /. Cefoperazone is a cephalosporin antibiotic for inhibition of rMrp2-mediated [3H]EβG uptake with IC50 of μM. Target: Antibacterial Cefoperazone is a sterile, semisynthetic, broad-spectrum, parenteral cephalosporin antibiotic for intravenous or intramuscular administration.To obtain useful informations for determining the optimal dosage of drugs in patients with impaired liver function, pharmacokinetics of cefoperazone (CPZ) was studied in healthy adults (normal control group) and 35 patients with liver disease (liver disease group).Cefoperazone (PDF Version) dosage reduction may be necessary in patients with liver dysfunction, concomitant alcohol use (disulfiram-like reaction), patients with a poor nutritional status, malabsorption states (eg, cystic fibrosis), alcoholism, and patients on prolonged hyperalimentation regimens are at high risk for cefoperazone-induced.